# TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy

> **NCT03394118** · PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 63 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT03394118
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-11
- **Primary completion:** 2021-03-11
- **Final completion:** 2021-04-08
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2021-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03394118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03394118, "TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03394118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*